Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

September 14 Live From WCLC 2026: Monday Highlights
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference and ask what changes in clinic on Monday.
A ROS1 drug that protects the brain and a first line combination that could not beat a decade old standard. Dr. Alexander Drilon brings the first line ARROS-1 data on zidesamtinib, and Dr. Giannis Mountzios walks us through EVOKE-03, sacituzumab govitecan plus pembrolizumab in PD-L1 high lung cancer.
Guests:
Alexander Drilon, MD
Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
Attending Physician, Thoracic Oncology Service
Giannis Mountzios, MD, MSc, PhD
Medical Oncologist and Director at the 4th Oncology Department and Clinical Trials Unit
Henry Dunant Hospital Center
Athens, Greece,
32 min
September 14 Live From WCLC 2026: Sunday Highlights
From the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, Dr. Narjust Florez talks with Dr. Chad Rusthoven about MAVERICK, the trial that tested MRI surveillance alone against prophylactic cranial irradiation in small cell lung cancer, and with Dr. Chul Kim about the final overall survival results of PAPILLON, amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC.
Both guests share what patients and community oncologists should take from the data.
Guests:
Chul Kim, MD, MPH
Thoracic Medical Oncologist and Associate Professor
Georgetown University
Chad G. Rusthoven, MD
Adjunct Associate Professor
University of Colorado
University of North Carolina at Chapel Hill
48 min
September 04 Before You Go: A Practical Guide to WCLC 2026 in Seoul
Get ready for WCLC 2026 in Seoul with Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez. From preparing for the flight and beating jet lag to navigating COEX, networking, exploring Seoul’s food scene, and making the most of the meeting, they share practical tips to help attendees arrive prepared and enjoy the full WCLC experience.
39 min
September 01 Beyond Stage IV: Rethinking Oligometastatic Lung Cancer
In this episode, Dr. Narjust Florez is joined by Dr. Yasir Elamin and Dr. Liliana Faroni to explore the evolving management of oligometastatic lung cancer. They break down key definitions, discuss when and how to use consolidative therapies like radiation and surgery, and examine patient selection, limitations, and emerging tools such as ctDNA that are shaping a more precise approach to care.
Guests:
Yasir Elamin, MD
Associate Professor of Thoracic Medical
University of Texas MD Anderson Cancer Center
Liliana Faroni, MD, PhD
Radiation Oncologist,
Oncologia D’Or Rio de Janeiro
48 min
August 28 LCC in Korean: The Role of Immunotherapy in Lung Cancer
In this Korean-language episode of Lung Cancer Considered, Dr. Chul Kim is joined by Dr. Hye-Ryun Kim and Dr. Young Kwang Chae to discuss the evolving role of immunotherapy across the lung cancer treatment continuum. They explore perioperative strategies for resectable NSCLC, treatment selection and biomarkers in advanced disease, emerging research, and what they are looking forward to at WCLC 2026 in Seoul.
Guest Host:
Chul Kim, MD, MPH
Thoracic Medical Oncologist and Associate Professor
Georgetown University
Guests:
Hye Ryun Kim, MD, PhD
Medical Oncologist
Chief of Lung Cancer Center
Yonsei Cancer Center
Young Kwang Chae, MD, MPH, MBA
Professor, Division of Hematology Oncology, Department of Medicine
Northwestern University Feinberg School of Medicine
47 min
August 25 The Global Fight Against Lung Cancer: A Conversation with WHO's José Luis Castro
Host Dr. Stephen Liu is joined by José Luis Castro, WHO Director-General Special Envoy for Chronic Respiratory Diseases, for a thought-provoking discussion on why lung cancer must be recognized as a global health priority. They explore the challenges of raising awareness, reducing stigma, expanding equitable access to lung cancer screening and care, and advancing the policies and partnerships needed to improve outcomes worldwide. The conversation also offers a preview of Castro's keynote message ahead of his appearance at the 2026 World Conference on Lung Cancer (WCLC) in Seoul this September.
Guest:
José Luis Castro
World Health Organization (WHO)
Director-General Special Envoy for Chronic Respiratory Diseases
30 min
August 18 LCC: Grace Under Pressure: Navigating Burnout and Loss in Oncology
In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Mark Lewis and Dr. Michael Maddaus for a candid conversation about physician wellness, burnout, grief, and resilience. Drawing from their personal and professional experiences, they explore the hidden emotional toll of caring for patients with cancer, the limitations of the “just be more resilient” mindset, and the importance of self-compassion, vulnerability, and seeking support.
Dr. Mark Lewis is Director of Gastrointestinal Oncology at Intermountain Health. He has become a leading voice on physician well-being, patient-centered care, and the emotional realities of oncology practice.
Dr. Michael Maddaus is a cardiovascular and thoracic surgeon at the University of Minnesota.
48 min
August 14 LCC Advances in ALK+ Cancer in Cantonese
As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with Dr. Tony Mok, Dr. Chao Zhang, and Dr. Wen-Zhao Zhong. The discussion reviews advances in ALK+ non-small cell lung cancer (NSCLC).
47 min
August 04 Treating Advanced Thymic Cancers
Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined by Dr. Nicolas Girard and Dr. Erica Pietroluongo to discuss the diagnosis, staging, and treatment of thymoma and thymic carcinoma, including current standards of care, evolving systemic therapies, and promising areas of research. They also highlight the importance of international collaboration in advancing care for patients with these rare malignancies.
Guests:
Nicolas Girard, MD, PhD
Head of the Thorax Institute Curie Montsouris,
Institut Curie, Paris, France
Erica Pietroluongo, MD, PhD
Medical Oncologist, University Federico II, Naples
Visiting Scholar, University of Chicago
1 hr
July 28 FDA Approval: Zidesamtinib and ROS1 NSCLC
Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer.
Guests:
Alexander Drilon, MD
Chief, Early Drug Development Service
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
Rosario Charo Garcia Campelo, MD
Head of Medical Oncology and Thoracic Tumor Unit, Chair, University Hospital
Head of the Oncology Research Group, Biomedical Research Institute A Coruna Spain
25 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.